Ignite Creation Date:
2024-05-05 @ 11:58 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00190333
Status:
COMPLETED
Last Update Posted:
2011-02-18
First Post:
2005-09-13
Brief Title:
Serotonin Transporter Inhibitor Escitalopram in Pulmonary Hypertension
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Assistance Publique - Hôpitaux de Paris
Study Overview
Official Title:
Evaluation of the Therapeutic Effects of Escitalopram in Pulmonary Hypertension Either Primary or Associated
Status:
COMPLETED
Status Verified Date:
2007-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase III multicenter randomized double-blind placebo-controlled study to evaluate the efficacy of escitalopram 30 mgday in two parallel groups randomization ratio escitalopram 2placebo 1
Detailed Description:
Primary objective to evaluate the efficacy of oral escitalopram at the dosage of 30 mgday for 16 weeks on the 6-minute walking test in patients with pulmonary hypertension
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None